Go Deep
Bafna Pharmaceuticals Limited
Bafna Pharmaceuticals Limited Score & Ratio Trend
| Date | Score | P/E | P/B | D/E | Price |
|---|---|---|---|---|---|
| Sep 2026 | 20,400 | 108.5 | 8.79 | 0.39 | 357.05 |
| Sep 2026 | 20,400 | 108.5 | 8.79 | 0.39 | 357.05 |
| Oct 2026 | 19,392 | 114.8 | 9.32 | 0.39 | 378.75 |
| Oct 2026 | 18,147 | 127.1 | 10.28 | 0.39 | 418.00 |
Bafna Pharmaceuticals Limited Quarterly Results
| Line Item | Jun 2026 | Mar 2026 | Dec 2025 | Sep 2025 |
|---|---|---|---|---|
| Revenue | 265,832,000.0 | 422,393,000.0 | 382,858,000.0 | 354,682,000.0 |
| Net Profit | 751,000.0 | 27,491,000.0 | 18,369,000.0 | 31,249,000.0 |
| EPS | 0.0 | 1.2 | 0.8 | 1.3 |
Bafna Pharmaceuticals Limited Revenue & Profit: Last 5 Years
| Line Item | Mar 2026 | Mar 2025 | Mar 2024 | Mar 2023 | Mar 2022 |
|---|---|---|---|---|---|
| Revenue | 1,506,174,000.0 | 1,458,570,000.0 | 1,524,657,000.0 | 1,153,499,000.0 | — |
| Net Profit | 110,998,000.0 | 41,525,000.0 | 73,479,000.0 | 113,380,000.0 | — |
| EPS | 4.7 | 1.8 | 3.1 | 4.8 | — |
Bafna Pharmaceuticals Limited Balance Sheet
| Line Item | Mar 2026 | Mar 2025 | Mar 2024 | Mar 2023 | Mar 2022 |
|---|---|---|---|---|---|
| Total Assets | 1,755,324,000.0 | 1,530,791,000.0 | 1,476,816,000.0 | 1,295,832,000.0 | — |
| Total Liabilities | 793,828,000.0 | 682,726,000.0 | 668,429,000.0 | 561,286,000.0 | — |
| Total Equity | 961,496,000.0 | 848,065,000.0 | 808,387,000.0 | 734,546,000.0 | — |
Owes vs Owns
Bafna Pharmaceuticals Limited owed ₹0.45 for every ₹1 it owned in Mar 2026, up from ₹0.43 in Mar 2023.
| Period | Mar 2026 | Mar 2025 | Mar 2024 | Mar 2023 |
|---|---|---|---|---|
| Owes vs Owns | 0.45× | 0.45× | 0.45× | 0.43× |
Everything the company owes ÷ everything it owns. Below 1× it owns more than it owes; above 1× it owes more than it owns.
Bafna Pharmaceuticals Limited Assets & Liabilities Breakdown (₹ Cr)
What it owns — Mar 2026
Cash & short-term investments 1.2%Receivables 25.0%Inventory 16.5%Fixed assets (tangible) 48.4%Other assets 9.0%
How it's funded — Mar 2026
Short-term debt 11.2%Long-term debt 10.1%Payables 17.8%Other liabilities 6.1%Shareholders' equity 54.8%
| Line Item | Mar 2026 | Mar 2025 | Mar 2024 | Mar 2023 |
|---|---|---|---|---|
| Assets | ||||
| Cash & short-term investments | 2.0 | 3.4 | 1.4 | 7.8 |
| Receivables | 43.9 | 40.2 | 45.4 | 41.1 |
| Inventory | 28.9 | 28.1 | 29.6 | 22.2 |
| Fixed assets (tangible) | 84.9 | 66.1 | 50.7 | 40.2 |
| Intangible assets | 0.0 | 0.0 | 1.8 | 1.5 |
| Long-term investments | 0.0 | 0.0 | 0.7 | 0.0 |
| Other assets | 15.8 | 15.3 | 18.1 | 16.7 |
| Liabilities & equity | ||||
| Short-term debt | 19.7 | 14.2 | 13.6 | 14.5 |
| Long-term debt | 17.8 | 14.0 | 10.8 | 8.4 |
| Payables | 31.3 | 30.9 | 35.4 | 28.5 |
| Other liabilities | 10.7 | 9.1 | 7.0 | 4.7 |
| Shareholders' equity | 96.1 | 84.8 | 80.8 | 73.5 |
| Net tangible assets | 96.1 | 84.8 | 79.1 | 72.0 |
Bafna Pharmaceuticals Limited Cash Flow
| Line Item | Mar 2026 | Mar 2025 | Mar 2024 | Mar 2023 | Mar 2022 |
|---|---|---|---|---|---|
| Operating Activities | 153,708,000.0 | 221,359,000.0 | 94,848,000.0 | 49,525,000.0 | — |
| Investing Activities | -224,010,000.0 | -211,629,000.0 | -150,536,000.0 | -74,932,000.0 | — |
| Financing Activities | 56,224,000.0 | 10,637,000.0 | -8,454,000.0 | 101,771,000.0 | — |